Clinical advice papers on osimertinib
Thank you for your request dated 11 August 2023 under the Official Information Act 1982 (OIA) for information relating to osimertinib. You requested:
Can I please request the PTAC (19 May 2022 Meeting) clinical advice papers for the following proposal: osimertinib
We are pleased to provide you with the information you requested attached to this letter.
We have redacted a small amount of information from the documents as we consider this is necessary to:
- protect information where the making available of the information would be likely to unreasonably prejudice the commercial position of the person who supplied or who is the subject of the information (section 9(2)(b)(ii));
- protect information which is subject to an obligation of confidence or which any person has been or could be compelled to provide under the authority of any enactment, where the making available of the information would be likely to prejudice the supply of similar information, or information from the same source, and it is in the public interest that such information should continue to be supplied (section 9(2)(ba)(i));
- enable Pharmac to carry on, without prejudice or disadvantage, negotiations, including commercial negotiations (section 9(2)(j)).
We trust that this information answers your queries. Please note, you have the right to make a complaint to the Ombudsman about our response to your OIA, under section 28(3) of the OIA. Details of how to make a complaint(external link) are on the Ombudsman’s website.
To make information more freely available, we publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.